

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 57

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–91) and Recommended (1–52) International Nonproprietary Names can be found in *Cumulative List No. 11, 2004* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 57

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.


On trouvera d'autres listes de Dénominations communes internationales proposées (1–91) et recommandées (1–52) dans la *Liste récapitulative No. 11, 2004* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 57

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–91) y Recomendadas (1–52) se encuentran reunidas en *Cumulative List No. 11, 2004* (disponible sólo en CD-ROM).

Latin, English, French, Spanish: Recommended INN	Chemical name or description; Molecular formula; Graphic formula
DCI Recommandée	Nom chimique ou description; Formule brute; Formule développée
DCI Recomendada	Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada
abagovomabum* abagovomab	immunoglobulin G1, anti-idiotypic anti-[anti-(<i>Homo sapiens</i> cancer antigen 125, CA 125, MUC-16) <i>Mus musculus</i> monoclonal antibody OC125] <i>Mus musculus</i> monoclonal antibody ACA125, clone 3D5 gamma1 heavy chain disulfide with clone 3D5 kappa light chain; (223-223":226-226":228-228") trisulfide dimer
abagovomab	immunoglobuline G1, anti-idiotypic anti-[anti-(<i>Homo sapiens</i> cancer antigen 125, CA 125, MUC-16) anticorps monoclonal murin OC125] anticorps monoclonal murin ACA125, chaîne lourde gamma1 du clone 3D5 unie par un pont disulfure à la chaîne légère kappa du clone 3D5; dimère (223-223":226-226":228-228")-trisulfure
abagovomab	inmunoglobulina G1, anti-idiotipo anti-[anti-(<i>Homo sapiens</i> cancer antígeno 125, CA 125, MUC-16) anticuerpo monoclonal murino OC125] anticuerpo monoclonal murino ACA125, cadena pesada gamma1 del clon 3D5 unida por un puente disulfuro a la cadena ligera kappa del clon 3D5; dímero (223-223":226-226":228-228")-trisulfuro
	Heavy chain/Chaîne lourde/Cadena pesada QVKLQESGAE LARPGASVKL SCKASGYTFT NYWMQWVKQR PGQGLDWIGA 50 IYPGDGNTRY THKFKGKATL TADKSSSTAY MQLSSLASED SGVYYCARGE 100 GNYAWFAYWG QGTTVTVSSA KTTPPSVYPL APGSAAQTNS MVTGLGCLVKG 150 YFPEPVTVTW NSGSLSSGVH TFPVAVLQSDL YTLSSSVTVP SSTWPSSETVT 200 CNVAHPASST KVDKKIVPRD CGCKPCICTV PEVSSVFIFP PKPKDVLITIT 250 LTPKVTVCVV DISKDDPEVQ FSWFVDDVEV HTAQTPREE QFNSTFRSVS 300 ELPIMHQDWL NGKEFKCRVN SAAFPAPIEK TISKTGRPK APQVYTIPTP 350 KEQMAKDKVS LTCMITDFFP EDITVEWQWN GQPAENYKNT QPIMDTDGSY 400 FVYSKLVNQK SNWEAGNTFT CSVLHEGLHN HHTKSLSHS PGK 443
	Light chain/Chaîne légère/Cadena ligera DIELTQSPAS LSASVGETVT ITCQASENIY SYLAWHQKQK GKSPQLLVYN 50 AKTLAGGVSS RFGSGSGTH FSLKIKSLQP EDFGIYYCQH HYGILPTFGG 100 GTKLEIKRAD AAPTVSIFPP SSEQLTSGGA SVVCFLNNFY PKDINVKWKI 150 DGSERQNGVL NSWTDQDSKD STYSMSSTLT LTKDEYERHN SYTCEATHKT 200 STSPIVKSFN RNEC 214
acidum iodofilticum (¹²³I) iodofiltic acid (¹²³ I)	(3 <i>RS</i>)-15-[4- ¹²³ I]iodophenyl]3-methylpentadecanoic acid
acide iodofiltique (¹²³ I)	acide (3 <i>RS</i>)-15-(4- ¹²³ I]iodophényl)-3-méthylpentadécanoïque
ácido iodofiltico (¹²³ I)	ácido (3 <i>RS</i>)-15-(4- ¹²³ I]iodofenil)-3-metilpentadecanoico
	C ₂₂ H ₃₅ ¹²³ IO ₂
	 and enantiomer et énantiomère y enantiómero

aclidinii bromidum


aclidinium bromide

(3R)-3-[(hydroxy)di(thiophen-2-yl)acetyloxy]-1-(3-phenoxypropyl)-1 λ -azabicyclo[2.2.2]octan-1-ylum bromide

bromure d'aclidinium

bromure de (3R)-3-[[hydroxybis(thiophén-2-yl)acétyl]oxy]-1-(3-phénoxypropyl)-1-azoniabicyclo[2.2.2]octane

bromuro de aclidinio

bromuro de (3R)-1-(3-fenoxipropil)-3-[(hidroxi)di(tiofen-2-il)acetiloxi]-1 λ -azabicyclo[2.2.2]octan-1-ilioC₂₆H₃₀BrNO₄S₂**afimoxifenum**

afimoxifene


4-(1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl)phenol

afimoxifène

4-[1-[4-[2-(diméthylamino)éthoxy]phényl]-2-phénylbut-1-ényl]phénol

afimoxifeno

4-[1-[4-[2-(dimetilamino)etoxi]fenil]-2-fenilbut-1-enil]fenol

C₂₆H₂₉NO₂and Z isomer
et l'isomère Z
y el isómero Z**afiberceptum***

afibercept

des-432-lysine-[human vascular endothelial growth factor receptor 1-(103-204)-peptide (containing Ig-like C2-type 2 domain) fusion protein with human vascular endothelial growth factor receptor 2-(206-308)-peptide (containing Ig-like C2-type 3 domain fragment) fusion protein with human immunoglobulin G1-(227 C-terminal residues)-peptide (Fc fragment)], (211-211':214-214')-bisdisulfide dimer

afibercept

(211-211':214-214')-bisdisulfure du dimère de la dès-432-lysine-[récepteur 1 humain du facteur de croissance endothélial vasculaire-(103-204)-peptide (contenant le domaine Ig-like C2-type 2) protéine de fusion avec le récepteur 2 humain du facteur de croissance endothélial vasculaire-(206-308)-peptide (contenant un fragment du domaine Ig-like C2-type 3) protéine de fusion avec l'immunoglobuline G1 humaine-(227 résidus C-terminaux)-peptide (fragment Fc)]

afibercept

(211-211':214-214')-bisdisulfuro del dímero de la des-432-lisina-[receptor 1 humano del factor de crecimiento endotelial vascular-(103-204)-péptido (que contiene el dominio Ig-like C2-tipo 2) proteína de fusión con el receptor 2 humano del factor de crecimiento endotelial vascular-(206-308)-péptido (que contiene un fragmento del dominio Ig-like C2-tipo 3) proteína de fusión con la inmunoglobulina G1 humana-(227 restos C-terminales)-péptido (fragmento Fc)]

C₄₃₁₈H₆₇₈₈N₁₁₆₄O₁₃₀₄S₃₂

Monomer / Monomère / Monómero

SDTGRPFVEM	YSEIPEIIHM	TEGRELVIPC	RVTSPNITVT	LKKFPLDTLI	50
PDGKRIIWDS	RKGFIIISNAT	YKEIGLLTCE	ATVNGHLYKT	NYLTHRQTNT	100
IIDVVLSPSH	GIELSVGEKL	VLNCTARTEL	NVGIDFNWEY	PSSKHQHKKL	150
VNRDLKTQSG	SEMKKFLSTL	TIDGVTRSDQ	GLYTCAASSG	MTKKNSTFV	200
RVHEKDKTHT	CPPCPAPELL	GGPSVFLFPP	KPKDTLMISR	TPEVTCVVVD	250
VSHEDPEVKF	NWYVDGVEVH	NAKTKPREEQ	YNSTYRVVSV	LTVLHQDWLN	300
GKEYKCKVSN	KALPAPIEKT	ISKAKGQPRE	PQVYTLPPSR	DELTKNQVSL	350
TCLVKGFYPS	DIAVEWESNG	QPENNYKTTT	PVLDSGGSFF	LYSKLTVDKS	400
RWQQGNVFSC	SVMHEALHNN	YTQKSLSLSP	G		431

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

30'-79' 30'-79' 124'-185' 124'-185' 211'-211'
 214'-214' 246'-306' 246'-306' 352'-410' 352'-410'

aleglitazarum

aleglitazar


(2S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid

aléglitazar

acide (2S)-2-méthoxy-3-[4-[2-(5-méthyl-2-phényl-1,3-oxazol-4-yl)éthoxy]-1-benzothiophén-7-yl]propanoïque

aleglitazar

ácido (2S)-3-[4-[2-(2-fenil-1,3-oxazol-5-metil-4-il)etoxi]-1-benzotiofen-7-il]-2-metoxipropanoico

C₂₄H₂₃NO₅S

alferminogenum tadenovecum*

alferminogene tadenovec

recombinant human adenovirus 5 (replication-deficient, E1-deleted) containing a human fibroblast growth factor-4 cDNA sequence driven by a cytomegalovirus promoter

alferminogène tadénovec

adénovirus 5 humain recombinant (réplication-déficient, région E1-supprimée) contenant la séquence ADN-copie du facteur 4 de croissance du fibroblaste humain sous contrôle d'un promoteur de cytomégalovirus

alferminogén tadenovec

adenovirus 5 humano recombinante (replicación-deficiente, con delección E1) que contiene la secuencia DNA-copia del factor-4 de crecimiento de fibroblastos humanos controlado por un promotor de citomegalovirus

apilimodum

apilimod


1-[(3-methylphenyl)methylidene]-2-{6-(morpholin-4-yl)-2-[2-(pyridin-2-yl)ethoxy]pyrimidin-4-yl}hydrazine

apilimod

1-(3-méthylbenzylidène)-2-[6-(morpholin-4-yl)-2-[2-(pyridin-2-yl)éthoxy]pyrimidin-4-yl]diazane

apilimod

1-(3-metilbencilideno)-2-[6-(morfolin-4-il)-2-[2-(piridin-2-il)etoxi]=pirimidin-4-il]diazano

 $C_{23}H_{26}N_6O_2$ **apricitabinum**


apricitabine

4-amino-1-[(2*R*,4*R*)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl]pyrimidin-2(1*H*)-one

apricitabine

(-)-4-amino-1-[(2*R*,4*R*)-2-(hydroxyméthyl)-1,3-oxathiolan-4-yl]=pyrimidin-2(1*H*)-one

apricitabina

(-)-4-amino-1-[(2*R*,4*R*)-2-(hidroximetil)-1,3-oxatiolan-4-il]pirimidin-2(1*H*)-ona $C_8H_{11}N_3O_3S$ **artemisonum**

artemisine


4-[(3*R*,5*aS*,6*R*,8*aS*,9*R*,10*R*,12*R*,12*aR*)-3,6,9-trimethyldecahydro-12*H*-3,12-epoxypyran[4,3-*j*][1,2]benzodioxepin-10-yl]=thiomorpholine-1,1-dione

artémisone

1,1-dioxyde de 4-[(3*R*,5*aS*,6*R*,8*aS*,9*R*,10*R*,12*R*,12*aR*)-3,6,9-triméthyldécahydro-3,12-époxyprano[4,3-*j*]-1,2-benzodioxépin-10-yl]thiomorpholine

artemisona

1,1-dióxido de 4-[(3*R*,5*aS*,6*R*,8*aS*,9*R*,10*R*,12*R*,12*aR*)-3,6,9-trimetildecáhido-3,12-epoxipirano[4,3-*j*]-1,2-benzodioxepin-10-il]=tiomorfolina

C₁₉H₃₁NO₆S**ataciceptum***

atacicept

[86-serine, 101-glutamic acid, 196-serine, 197-serine, 222-aspartic acid, 224-leucine][human tumor necrosis factor receptor superfamily member 13B-(30-110)-peptide (TACI fragment containing TNFR-Cys 1 and TNFR-Cys 2) fusion protein with human immunoglobulin G1-(232 C-terminal residues)-peptide (γ1-chain Fc fragment), (92-92':95-95')-bisdisulfide dimer

atacicept

(92-92':95-95')-bisdisulfure du dimère de la [86-sérine, 101-acide glutamique, 196-sérine, 197-sérine, 222-acide aspartique, 224-leucine]-protéine de fusion du membre 13B humain de la superfamille des récepteurs du facteur de nécrose tumorale-(30-110)-peptide (portion du TACI incluant les deux régions riches en cystéine) avec l'immunoglobuline G1 humaine-(232 résidus C-terminaux)-peptide (fragment Fc de la chaîne γ1)

atacicept

92-92':95-95')-bisdisulfuro del dímero de la [86-serina, 101-ácido glutámico, 196-serina, 197-serina, 222-ácido aspártico, 224-leucina]-proteína de fusión del miembro 13B humano de la superfamilia de receptores del factor de necrosis tumoral-(30-110)-péptido (porción del TACI que incluye las dos regiones ricas en cisteína) con la inmunoglobulina G1 humana-(232 restos C-terminales)-péptido (fragmento Fc de la cadena γ1)

C₃₁₀₄H₄₇₈₈N₈₅₆O₉₅₀S₄₄

Monomer / Monomère / Monómero				
AMRSCPEEQY	WDPLLGTGMS	CKTICNHQSQ	RTCAAFCRSL	SCRKEQGKFY 50
DHLLRDCISC	ASICGQHPKQ	CAYFCENKLR	SEPKSSDKTH	TCPPCPAPEA 100
EGAPSVFLFP	PKPKDÖLMIS	RTPEVTCVVV	DVSHEDPEVK	FNWYVDGVEV 150
HNAKTKPREE	QYNSTYRVVS	VLTVLHQDWL	NGKEYKCKVS	NKALPSSIEK 200
TISKAKGQPR	EPQVYTLPPS	RDELTKNQVS	LTCLVKGFYP	SDIAVEWESN 250
GQPENNYKTT	PPVLDSDGSF	FLYSKLTVDK	SRWQQGNVFS	CSVMHEALHN 300
HYTQKSLSLS	PGK			313

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 5-18 5'-18' 21-33 21'-33' 25-37 25'-37' 42-57 42'-57' 60-71
 60'-71' 64-75 64'-75' 92-92' 95-95' 127-187 127'-187' 233-291 233'-291'

azilsartanum

azilsartan



2-ethoxy-1-[[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,1'-biphenyl-4-yl]methyl]-1*H*-benzimidazole-7-carboxylic acid

azilsartan

acide 2-éthoxy-1-[[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)=biphényl-4-yl]méthyl]-1*H*-benzimidazole-7-carboxylique

azilsartán

ácido 2-etoxi-1-[[2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil]-1*H*-bencimidazol-7-carboxílico



bavituximabum*
bavituximab


immunoglobulin G1, anti-(phosphatidylserine) chimeric monoclonal ch3G4; gamma1 heavy chain (*Mus musculus* VH-*Homo sapiens* IGHG1) (223-214')-disulfide with kappa light chain (*Mus musculus* V-KAPPA-*Homo sapiens* IGKC); (229-229':232-232'')-bisdisulfide dimer

bavituximab

immunoglobuline G1, anti-(phosphatidylsérine) anticorps monoclonal chimérique ch3G4; chaîne lourde gamma1 (*Mus musculus* VH-*Homo sapiens* IGHG1) (223-214')-disulfure avec la chaîne légère kappa (*Mus musculus* V-KAPPA-*Homo sapiens* IGKC); dimère (229-229":232-232'')-bisdisulfure

bavituximab

inmunoglobulina G1, anti-(fosfatidilserina) anticuerpo monoclonal quimérico ch3G4; cadena pesada gamma1 (*Mus musculus* VH-*Homo sapiens* IGHG1) (223-214')-disulfuro con la cadena ligera kappa (*Mus musculus* V-KAPPA-*Homo sapiens* IGKC), dímero (229-229":232-232'')-bisdisulfuro



Heavy chain / Chaîne lourde / Cadena pesada				
EVQLQSGPE	LEKPGASVKL	SCKASGYSFT	GYNMNWKQS	HGKSLEWIGH 50
IDPYYGDSY	NQKFRGKATL	TVDKSSSTAY	MQLKSLTSED	SAVYYCVKGG 100
YYGHWYFDVW	GAGTTVTVSS	ASTKGPSVFP	LAPSSKSTSG	GTAALGCLVK 150
DYFPEPVTVS	WNSGALTSGV	HTFPAVLQSS	GLYSLSSVVT	VPSSSLGTQT 200
YICNVNHKPS	NTKVDKKVEP	KSCDKTHTCP	PCPAPELLGG	PSVFLFPPKP 250
KDTLMISRTP	EVTQVVDVDS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN 300
STYRVVSVLT	VLHQDWLNGK	EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ 350
VYTLPPSRDE	LTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTTPV 400
LDSDGSFFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPGK 450
k Chain / Chaîne k / Cadena k				
DIQMTQSPSS	LSASLGERVS	LTCRASQDIG	SSLNWLQQGP	DGTIKRLIYA 50'
TSSLDSGVPK	RFSGSRSGSD	YSLTISSLES	EDFVDYYCLQ	YVSSPPTFGA 100'
GTKLELKRAD	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV 150'
DNALQSGNSQ	ESVTEQDSKD	STYLSSTLT	LSKADYEKKH	VYACEVTHQG 200'
LSSPVTKSFN	RGEC			214'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 22-96 22"-96" 23'-88' 23"-88"" 134'-194' 134"-194"" 147'-203 147"-203"
 214'-223 214"-223" 229-229" 232-232" 264-324 264"-324" 370-428 370"-428"

bedoradrinum

bedoradrine


2-[[[(7S)-7-[(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyethyl)phenyl]ethyl]amino]-5,6,7,8-tetrahydronaphthalen-2-yl]oxy]-N,N-dimethylacetamide

bédoradrine

(-)-2-[[[(7S)-7-[(2R)-2-hydroxy-2-[4-hydroxy-3-(2-hydroxyéthyl)phényl]éthyl]amino]-5,6,7,8-tétrahydronaphtalén-2-yl]oxy]-N,N-diméthylacétamide

bedoradrina

(-)-2-[[[(7S)-7-[(2R)-2-hidroxi-2-[4-hidroxi-3-(2-hidroxietil)fenil]etil]amino)-5,6,7,8-tetrahidronaftalen-2-il]oxi]-N,N-dimetilacetamida

C₂₄H₃₂N₂O₅**beperminogenum perplasmidum***

beperminogene perplasmid

plasmid DNA containing human hepatocyte growth factor cDNA sequence driven by a cytomegalovirus promoter

béperminogène perplasmide

ADN plasmidique contenant la séquence ADN-copie du facteur de croissance de l'hépatocyte humain sous contrôle d'un promoteur de cytomégalo virus

beperminogén perplásmido

DNA de plásmido que contiene la secuencia DNA-copia del factor de crecimiento del hepatocito humano controlado por un promotor de citomegalovirus

beroctocogum alfa*

beroctocog alfa


human blood-coagulation factor VIII-(1-740)-peptide complex with human blood-coagulation factor VIII-(1649-2332)-peptide

béroctocog alfa

combinaison du facteur VIII de coagulation humain-(1-740)-peptide (chaîne lourde du facteur VIIIa, isoforme de 92 kDa) avec le facteur VIII de coagulation humain-(1649-2332)-peptide (chaîne légère du facteur VIIIa)

beroctocog alfa

combinación del factor VIII de coagulación humano-(1-740)-péptido (cadena pesada del factor VIIIa, isoforma de 92 kDa) con el factor VIII de coagulación humano-(1649-2332)-péptido (cadena ligera del factor VIIIa)



Heavy chain / Chaîne lourde / Cadena pesada				
ATRRYYLGAV	ELSWDYMQSD	LGELPVDARF	PPRVPKSFPF	NTSVVYKCTL 50
FVEFTDHLFN	IAKPRPPWVG	LLGPTIQAEV	YDTVVITLKN	MASHPVSLHA 100
VGVSYWKAKE	GAEYDDQTSQ	REKEDDKVFP	GGSHTYVWQV	LKENGPMASD 150
PLCLTYSYLS	HVDLVKDLNS	GLIGALLVCR	EGSLAKEKTQ	TLHKFILLFA 200
VFDEGKSWHS	ETKNSLMQDR	DAASARAWPK	MHTVNGYVNR	SLPGLIGCHR 250
KSVYWHVIGM	GTTPEVHSIF	LEGHTFLVRN	HRQASLEISP	ITFLTAQTLL 300
MDLGQFLLFC	HISSHQHDGM	EAYVKVDSCP	EEPQLRMKNN	EEAEDYDDL 350
TDSEMDVVR	DDNNSPSFIQ	IRSVAKKHPK	TWVHYIAEEE	EDWDYAPLVL 400
APDDRSYKSQ	YLNNGPQRIG	RKYKKVRFMA	YTDFTFKTRE	AIHESGILG 450
PLLYGEVGD	LLIIFKNQAS	RPYNIYPHGI	TDVRLYSRR	LPKGVKHLKD 500
FPILPGEIFK	YKWTVTVEDG	PTKSDPRCLT	RYSSSFVNME	RDLASGLIGP 550
LLICYKESVD	QRGNQIMSDK	RNVILFSVFD	ENRSWYLTEN	IQRFLPNPAG 600
VQLEDPEFQA	SNIMHSINGY	VFDLQLSVC	LHEVAYWYIL	SIGAQTDFLS 650
VFFSGYTFKH	KMVEDTLTL	FPFSGETVFM	SMENPGLWIL	GCHNSDFRNR 700
GMTALLKVSS	CDKNTGDYEE	DSYEDISAYL	LSKNNAIEPR	S 741

Light chain / Chaîne légère / Cadena ligera				
TRTTLQSDQE	EIDYDDTISV	EMKKEDFDIY	DEDENQSPRS	FQKTRHYFI 1700
AAVERLWDYG	MSSSPHVLNR	RAQSGSVPQF	KKVVFQEFTD	GSFTQPLYRG 1750
ELNEHLGLLG	PYIRAEVEDN	IMVTFRNQAS	RPYSFYSSLI	SYEEDQRQGA 1800
EPRKNFVKPN	ETKTYFWKVQ	HMMAPTKEDEF	DKAWAYFSD	VDLEKDVHSG 1850
LIGPLLVCHT	NTLNPAGHRQ	VTVQEFALFF	TIFDETCSWY	FTENMERNCR 1900
APCNIQMEDP	TFKENYRFHA	INGYIMDTLP	GLVMAQDQRI	RWYLLSMGSN 1950
ENIHSIHFSG	HVFTVRKKEE	YKMALYNLYP	GVFETVEMLP	SKAGIWRVEC 2000
LIGEHLHAGM	STLFLVYSNK	CQTPLGMSG	HIRDFQITAS	GQYGQWAPKL 2050
ARLHYSGSIN	AWSTKEPFSW	IKVDLLAPMI	IHGKIQGAR	QKFSSLYISQ 2100
FIIMYSLDGK	KWQTYRGNST	GTLMVFFGNV	DSSGIKHNIF	NPPIIARYIR 2150
LHPTHYSIRS	TLRMELMGCD	LNCSMPLGM	ESKAISDAQI	TASSYFTNMF 2200
ATWSPSKARL	HLQGRSNAWR	PQVNNPKEWL	QVDFQKTMKV	TGVTQTGVKS 2250
LLTSMYVKEF	LISSSQDGHQ	WTLFFQNGKV	KVFGQNDQSF	TPVNSLDPP 2300
LLTRYLRHP	QSWVHQIALR	MEVLGCEAQD	LY	2332

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
153-179 528-554 1899-1903 2021-2169 2174-2326

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
Asn-41 Asn-239 Asn-582 Asn-1810 Asn-2118

Modifications / Modificaciones
Y = 4-O-sulfotyrosyl

bremelanotidum
bremelanotide



2,7-anhydro(*N*-acetyl-L-2-aminohexanoyl-L-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysine)

brémelanotide

N-acétyl-L-2-aminohexanoyl-L-α-aspartyl-L-histidyl-D-phénylalanyl-L-arginyl-L-tryptophyl-L-lysine-(2→7)-lactame

bremelanotida

N-acetil-L-2-aminohexanoil-L-α-aspartil-L-histidil-D-fenilalanil-L-arginil-L-triptofil-L-lisina-(2→7)-lactama



bucelipasum alfa*

bucelipase alfa

human bile-salt-activated lipase (cholesterol esterase, EC 3.1.1.13),
glycoform alfa (recombinant hBSSL)

bucélipase alfa

lipase activée par les sels biliars humaine (cholestérol estérase,
EC 3.1.1.13), glycoforme alpha (recombinante hBSSL)

bucelipasa alfa

lipasa humana activada por las sales biliares (colesterol esterasa,
EC 3.1.1.13), gliciforma alfa (recombinante hBSSL)C₃₄₃₄H₅₂₅₈N₈₉₄O₁₀₄₁S₁₇

AKLGAVYTEG	GFVEGVNKKL	GLLGDSVDIF	KGIPFAAPTK	ALENPQPHPG	50
WQGTCLKAKNF	KKRCLQATIT	QDSTYGDEDC	LYLNIWVPQG	RKQVSRDLPV	100
MIWIYGGAF	MGSGHGANFL	NNLYDGEEI	ATRGNVIVVT	FNYRVGPLGF	150
LSTGDANLPG	NYGLRDQHMA	IAWVKRNIAA	FGGDPNNITL	FGESAGGASV	200
SLQTLSPYNK	GLIRRAISQS	GVALSPWVIQ	KNPLFWAKKV	AEKVGCPVGD	250
AARMAQCCLKV	TDPRALTLAY	KVPLAGLEY	MLHYVGFVPV	IDGDFIPADP	300
INLYANAADI	DYIAGTNNMD	GHIFASIDMP	AINKGNKKVT	EEDFYKLVE	350
FTITKGLRGA	KTTFDVYTES	WAQDPSQENK	KKTVDVFETD	VLFLVPTEIA	400
LAQHRANAKS	AKTYAYLF	PSRMPVYPKW	VGADHADDIQ	YVFGKPFATP	450
TGYRPQDRTV	SKAMIAWNTN	FAKTGDPNMG	DSAVPTHWEP	YTTENSGYLE	500
ITKKMGSSSM	KRSLRTNFLR	YWTLYLALP	TVTDQEATPV	PPTGDSSEATP	550
VPPTGDSSETA	PVPPTGDSGA	PPVPPTGDSG	APPVPPTGDS	GAPPVPPTGD	600
SGAPPVPPTG	DSGAPPVPPT	GDSGAPPVPP	TGDSGAPPVP	PTGDAGPPPV	650
PPTGDSGAPP	VPPTGDSGAP	PVTPTGDSET	APVPPTGDSG	APPVPPTGDS	700
EAAPVPPTDD	SKEAQMPAVI	RF			722

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
64-80 246-257

Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación

Asn-187 Thr-538 Thr-549 Thr-559 Thr-576 Thr-587
Thr-598 Thr-609 Thr-620 Thr-631 Thr-642**camobucolum**


camobucol

4-{4-[(2-{[3,5-di(*tert*-butyl)-4-hydroxyphenyl]sulfanyl}propan-2-yl)=
sulfanyl]-2,6-di(*tert*-butyl)phenoxy}acetic acid

camobucol

acide 4-{4-[(2-{[3,5-di(*tert*-butyl)-4-hydroxyphényl]sulfanyl}propan-
2-yl)sulfanyl]-2,6-di(*tert*-butyl)phénoxy}acétique

camobucol

ácido 4-{4-[(2-{[3,5-di(*terc*-butil)-4-hidroxiifenil]sulfanil}propan-2-il)=
sulfanil]-2,6-di(*terc*-butil)fenoxi}acéticoC₃₃H₅₀O₄S₂**capadenosonum**

capadenoson


2-amino-6-({[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-
4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile

capadénoson

2-amino-6-[[[2-(4-chlorophényl)-1,3-thiazol-4-yl]méthyl]sulfanyl]-
4-[4-(2-hydroxyéthoxy)phényl]pyridine-3,5-dicarbonitrile

capadenosón

2-amino-6-({[2-(4-clorofenil)-1,3-tiazol-4-il]metil}sulfanil)-
4-[4-(2-hidroxietoxi)fenil]piridina-3,5-dicarbonitrilo

**catramilastum**



catramilast

1-[(2*S*)-2-[3-(cyclopropylmethoxy)-4-methoxyphenyl]propyl]-1,3-dihydro-2*H*-imidazol-2-one

catramilast

1-[(2*S*)-2-[3-(cyclopropylméthoxy)-4-méthoxyphényl]propyl]-1,3-dihydro-2*H*-imidazol-2-one

catramilast

1-[(2*S*)-2-[3-(ciclopropilmetoxi)-4-metoxifenil]propil]-1,3-dihidro-2*H*-imidazol-2-ona**cediranibum**



cediranib

4-[(4-fluoro-2-methyl-1*H*-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline

cédiranib

4-[(4-fluoro-2-méthyl-1*H*-indol-5-yl)oxy]-6-méthoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline

cediranib

4-[(4-fluoro-2-metil-1*H*-indol-5-il)oxi]-6-metoxi-7-[3-(pirrolidin-1-il)=propoxi]quinazolina**denibulinum**

denibulin


methyl [5-({4-[(2*S*)-2-aminopropanamido]phenyl}sulfanyl)-1*H*-benzimidazol-2-yl]carbamate

dénibuline

[5-[[4-[(2*S*)-2-aminopropanamido]phényl]sulfanyl]-1*H*-benzimidazol-2-yl]carbamate de méthyle

denibulina

[5-({4-[(2*S*)-2-aminopropanamido]fenil}sulfanil)-1*H*-bencimidazol-2-il]carbamato de metilo

**dexelvucitabinum**



dexelvucitabine

4-amino-5-fluoro-1-[(2*R*,5*S*)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1*H*)-one

dexelvucitabine

(+) 4-amino-5-fluoro-1-[(2*R*,5*S*)-5-(hydroxyméthyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1*H*)-one

dexelvucitabina

(+) 4-amino-5-fluoro-1-[(2*R*,5*S*)-5-(hidroximetil)-2,5-dihidrofuran-2-il]pirimidin-2(1*H*)-ona**efungumabum***

efungumab

immunoglobulin scFv fragment, anti-(heat shock protein 90 homolog from *Candida albicans* (yeast)), methionylalanyl-[human monoclonal HSP90mab VH domain (120 residues)]-tris[(tetraglycyl)seryl]-[human monoclonal HSP90mab V-KAPPA domain (107 residues)]-[arginyl-trialanyl-leucyl-glutamyl]-hexahistidine

éfungumab

immunoglobuline fragment scFv, anti-(homologue de la protéine de choc thermique 90 de *Candida albicans* (levure)), methionylalanyl-[domaine VH (120 résidus) de l'anticorps monoclonal humain HSP90mab]-tris[(tetraglycyl)seryl]-[domaine V-KAPPA (107 résidus) de l'anticorps monoclonal humain HSP90mab]-[arginyl-trialanyl-leucyl-glutamyl]-hexahistidine

efungumab

inmunoglobulina fragmento scFv, anti-(homólogo de la proteína de choc térmico 90 de *Candida albicans*), metionilalanil-[dominio VH (120 restos) del anticuerpo monoclonal humano HSP90mab]-tris[(tetraglicil)seril]-[dominio V-KAPPA (107 restos) del anticuerpo monoclonal humano HSP90mab]-[arginil-trialanil-leucil-glutamil]-hexahistidina

MAEVQLVES GAEVKKPGES LRISCKGSGC IISYWISWV RQMPGKGLEW
 MGKIDPGDSY INYSPSFQGH VTISADKSIN TAYLQWNSLK ASDTAMYYCA
 RGRDRFGDSF DYWGQGTTLVT VSSGGGGSGG GSGGGGSDV VMTQSPSFLS
 AFVGDRTIT CRASSGISRY LAWYQQAPGK APKLLIYAAS TLQTGVPSRF
 SGSGSGTEFT LTINSLQPED FATYYCQHLN SYPLTFGGGT KVDIKRAAA
 LEhhhhhh

elocalcitolum


elocalcitol

(1*S*,3*R*,5*Z*,7*E*,23*E*)-1-fluoro-26,27-dihomo-9,10-secocholesta-5,7,10(19),16,23-pentaene-3,25-diol

élocalcitol

(1*R*,5*S*)-3-[(1*Z*)-2-[(3*aS*,4*E*,7*aS*)-1-[(1*S*,3*E*)-5-éthyl-5-hydroxy-1-méthylhept-3-ényl]-7*a*-méthyl-3,3*a*,5,6,7,7*a*-hexahydro-4*H*-indén-4-ylidène]éthylidène]-5-fluoro-4-méthylidénecyclohexanol

elocalcitol

(1*S*,3*R*,5*Z*,7*E*,23*E*)-1-fluoro-26,27-dihomo-9,10-secocholesta-5,7,10(19),16,23-pentaeno-3,25-diolC₂₉H₄₃FO₂**elsibucolum**


elsibucol

4-{4-[(2-{[3,5-di-*tert*-butyl-4-hydroxyphenyl]sulfanyl}propan-2-yl)=sulfanyl]-2,6-di-*tert*-butylphenoxy}butanoic acid

elsibucol

acide 4-[4-[[1-[[3,5-bis(1,1-diméthyléthyl)-4-hydroxyphényl]sulfanyl]-1-méthyléthyl]sulfanyl]-2,6-bis(1,1-diméthyléthyl)phénoxy]butanoïque

elsibucol

ácido 4-[4-[(2-{[3,5-di-*terc*-butil-4-hidroxifenil]sulfanil}propan-2-il)=sulfanil]-2,6-di-*terc*-butilfenoxi]butanoicoC₃₅H₅₄O₄S₂**epoetinum theta**

epoetin theta

human erythropoietin-(1-165)-peptide, glycoform θ

époétine thêta

érythropoïétine humaine-(1-165)-peptide, glycoforme θ

epoetina zeta

eritropoyetina humana-péptido-(1-165), glicofoma θ

C₈₀₉H₁₃₀₁N₂₂₉O₂₄₆S₅

ferroquinum


ferroquine

N'-(7-chloroquinolin-4-yl)-*N,N*-dimethyl-*C,C'*-(ferrocene-1,2-diyl)=dimethanamine

ferroquine

N'-(7-chloroquinoléin-4-yl)-*N,N*-diméthyl-*C,C'*-(férocène-1,2-diyl)=diméthanamine

ferroquina

N'-(7-cloroquinolin-4-il)-*N,N*-dimetil-*C,C'*-(ferroceno-1,2-diil)=dimetanamina $C_{23}H_{24}ClFeN_3$ **fluticasonum furoas**


fluticasone furoate

6 α ,9-difluoro-17-[[[(fluoromethyl)sulfanyl]carbonyl]-11 β -hydroxy-16 α -methyl-3-oxoandrosta-1,4-dien-17 α -yl] furan-2-carboxylate

furoate de fluticasone

furane-2-carboxylate de 6 α ,9-difluoro-17-[[[(fluorométhyl)sulfanyl]carbonyl]-11 β -hydroxy-16 α -méthyl-3-oxoandrosta-1,4-dién-17 α -yle]

furoato de fluticasona

furano-2-carboxilato de 6 α ,9-difluoro-17-[[[(fluorometil)sulfanil]carbonyl]-11 β -hidroxi-16 α -metil-3-oxoandrosta-1,4-dien-17 α -ilo] $C_{27}H_{29}F_3O_6S$ **fosalvudinum tidoxilum**

fosalvudine tidoxil


(2*RS*)-2-(decyloxy)-3-[(dodecyl)sulfanyl]propyl [(2*R*,3*S*,5*R*)-3-fluoro-5-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)tetrahydrofuran-2-yl]methyl hydrogen phosphate

fosalvudine tidoxil

hydrogénophosphate de (2*RS*)-2-(décyloxy)-3-(dodécylsulfanyl)=propyle et de [(2*R*,3*S*,5*R*)-3-fluoro-5-(5-méthyl-2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)tétrahydrofuran-2-yl]méthyle

fosalvudina tidoxilo

hidrógenofosfato de (2*RS*)-2-(deciloxi)-3-[(dodecil)sulfanil]propilo y [(2*R*,3*S*,5*R*)-3-fluoro-5-(5-metil-2,4-dioxo-3,4-dihidropirimidin-1(2*H*)-il)tetrahidrofuran-2-il]metilo

$C_{35}H_{64}FN_2O_8PS$ 

gamithromycinum
gamithromycin


(2*R*,3*S*,4*R*,5*S*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-dideoxy-3-*C*-methyl-3-*O*-methyl-α-*L*-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-7-propyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-*D*-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclopentadecan-15-one

gamithromycin

(2*R*,3*S*,4*R*,5*S*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-didésoxy-3-*C*-méthyl-3-*O*-méthyl-α-*L*-ribo-hexopyranosyl)oxy]-2-éthyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexaméthyl-7-propyl-11-[[3,4,6-tridésoxy-3-(diméthylamino)-β-*D*-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclopentadécan-15-one

gamitromicina

(2*R*,3*S*,4*R*,5*S*,8*R*,10*R*,11*R*,12*S*,13*S*,14*R*)-13-[(2,6-didesoxi-3-*C*-metil-3-*O*-metil-α-*L*-ribo-hexopiranosil)oxi]-2-etil-3,4,10-trihidroxi-3,5,8,10,12,14-hexametil-7-propil-11-[[3,4,6-tridesoxi-3-(dimetilamino)-β-*D*-xylo-hexopiranosil]oxi]-1-oxa-7-azacipentadecan-15-ona

 $C_{40}H_{76}N_2O_{12}$ 

ilepatrilum
ilepatril


(4*S*,7*S*,12*bR*)-7-[(2*S*)-2-(acetylsulfanyl)-3-methylbutanamido]-6-oxo-1,2,3,4,6,7,8,12*b*-octahydropyrido[2,1-*a*][2]benzazepine-4-carboxylic acid

ilépatril

acide (4*S*,7*S*,12*bR*)-7-[[2*S*)-2-(acétylsulfanyl)-3-méthylbutanoil]amino]-6-oxo-1,2,3,4,6,7,8,12*b*-octahydropyrido[2,1-*a*][2]benzazépine-4-carboxylique

ilepatrilo

ácido (4*S*,7*S*,12*bR*)-7-[[2*S*)-2-(acetilsulfanil)-3-metilbutanoil]amino]-6-oxo-1,2,3,4,6,7,8,12*b*-octahidropirido[2,1-*a*][2]benzazepina-4-carboxílico

**imisopasemum manganum**

imisopasem manganese



(PBPY-7-11-2344'3')-dichloro[(4aR,13aR,17aR,21aR)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-icosahydro-7,11-(azeno)dibenzo[b,h][1,4,7,10]=tetraazacycloheptadecine-κ⁴N⁵,N¹³,N¹⁸,N²¹,N²²]manganese

imisopasem manganèse

(PBPY-7-11-2344'3')-dichloro[(4aR,13aR,17aR,21aR)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-icosahydro-11,7-nitrilo-7H-dibenzo[b,h][1,4,7,10]=tétraazacycloheptadécine-κN⁵,κN¹³,κN¹⁸,κN²¹,κN²²]manganèse

imisopasem manganeso

(PBPY-7-11-2344'3')-dicloro[(4aR,13aR,17aR,21aR)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-icosahidro-7,11-(azeno)dibenzo[b,h][1,4,7,10]=tetraazacicloheptadecino-κ⁴N⁵,N¹³,N¹⁸,N²¹,N²²]manganeso

**inakalantum**

inakalant



tert-butyl (2-{7-[(2*S*)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-yl}ethyl)carbamate

inakalant

[2-{7-[(2*S*)-3-(4-cyanophénoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]éthyl]carbamate de 1,1-diméthyléthyle

inakalant

(2-{7-[(2*S*)-3-(4-cianofenoxi)-2-hidroxiopropil]-9-oxa-3,7-diazabicyclo[3.3.1]nonan-3-il}etil)carbamato de *terc*-butilo



lapaquistatum

lapaquistat


(1-[[[(3*R*,5*S*)-1-(3-hydroxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl)acetic acid

lapaquistat

acide (1-[[[(3*R*,5*S*)-1-(3-hydroxy-2,2-diméthylpropyl)-7-chloro-5-(2,3-diméthoxyphényl)-2-oxo-1,2,3,5-tétrahydro-4,1-benzoxazépin-3-yl]acétyl]pipéridin-4-yl)acétique

lapaquistat

ácido (1-[[[(3*R*,5*S*)-1-[3-hidroxi-2,2-dimetilpropil]]-7-cloro-5-(2,3-dimetoxifenil)-2-oxo-1,2,3,5-tetrahidro-4,1-benzoxazepin-3-il]acetil]piperidin-4-il)acético

 $C_{31}H_{39}ClN_2O_8$ **levonadifloxacinum**

levonadifloxacin


(5*S*)-9-fluoro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-6,7-dihydro-1*H*,5*H*-benzo[*ij*]quinolizine-2-carboxylic acid

lévonadifloxacine

(-)-acide (5*S*)-9-fluoro-8-(4-hydroxypipéridin-1-yl)-5-méthyl-1-oxo-6,7-dihydro-1*H*,5*H*-benzo[*ij*]quinolizine-2-carboxylique

levonadifloxacino

ácido (5*S*)-9-fluoro-8-(4-hidroxipiperidin-1-il)-5-metil-1-oxo-6,7-dihidro-1*H*,5*H*-benzo[*ij*]quinolizina-2-carboxílico

 $C_{19}H_{21}FN_2O_4$ **lexatumumabum***

lexatumumab

immunoglobulin G1, anti-[human tumor necrosis factor receptor superfamily member 10B (TNFRSF10B, death receptor 5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL-R2, CD262)] human monoclonal HGS-ETR2; gamma1 heavy chain (*Homo sapiens* VH-IGHG1) (224-213')-disulfide with lambda light chain (*Homo sapiens* V-LAMBDA- IGLC2); (230-230'':233-233'')-bisdisulfide dimer

lexatumumab immunoglobuline G1, anti-[membre 10B de la superfamille des récepteurs du facteur de nécrose tumorale humain (TNFRSF10B, death receptor 5, TRAIL-R2, CD262)] anticorps monoclonal humain HGS-ETR2; chaîne lourde gamma1 (*Homo sapiens* VH-IGHG1) (224-213')-disulfure avec la chaîne légère lambda (*Homo sapiens* V-LAMBDA- IGLC2); dimère (230-230":233-233")-bisdisulfure

lexatumumab inmunoglobulina G1, anti-[miembro 10B de la superfamilia de receptores del factor de necrosis tumoral humano (TNFRSF10B, death receptor 5, TRAIL-R2, CD262)] anticuerpo monoclonal humano HGS-ETR2; cadena pesada gamma1 (*Homo sapiens* VH-IGHG1) (224-213')-disulfuro con la cadena ligera lambda (*Homo sapiens* V-LAMBDA- IGLC2); dímero (230-230":233-233")-bisdisulfuro

C₆₃₄₆H₉₈₃₂N₁₇₂₀O₂₀₀₂S₄₂

Heavy chain / chaîne lourde / cadena pesada
 EVQLVQSGGG VERPGGSLRL SCAASGFTFD DYGMSWVRQA PGKGLEWVSG 50
 INWNGGSGTGY ADSVKGRVTI SRDNAKNSLY LQMNSLRAED TAVYYCAKIL 100
 GAGRGGWYFDL WGKGTTVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
 KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ 200
 TYICNVNHKP SNTKVDKRVK PKSCDKHTC PPCPAPELLG GPSVFLFPPK 250
 PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
 NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
 QVYTLPPSRE EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTTP 400
 VLDSDDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG 450
 K

Lambda chain / chaîne lambda / cadena lambda
 SSELTDPAV SVALGQTVRI TCQGDLSRSY YASWYQKPG QAPVLVIYK 50
 NNRPSGIPDR FSGSSSGNTA SLTITGAQAE DEADYYCNSR DSGNHVVF 100
 GGTKLTVLGQ PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW 150
 KADSSPVKAG VETTTPSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE 200
 GSTVEKTVAP TECS

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 22-96 22'-87" 22"-96" 22"-87" 136'-195' 136"-195" 148-204 148"-204"
 213'-224 213"-224" 230-230" 233-233" 265-325 265"-325" 371-429 371"-429"

lifigiquatum
lifigiquat

[5-(1-benzyl-1*H*-indazol-3-yl)furan-2-yl]methanol


lifigiquat

[5-(1-benzyl-1*H*-indazol-3-yl)furan-2-yl]méthanol

lifigiquat

[5-(1-bencil-1*H*-indazol-3-il)furan-2-il]metanol

C₁₉H₁₆N₂O₂



lobeglitazonum
lobeglitazone



(5*R*)-5-[[4-(2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]methylamino]ethoxy)phenyl]methyl]-1,3-thiazolidine-2,4-dione

lobéglitazone

(5*R*)-5-[4-[2-[[6-(4-méthoxyphénoxy)pyrimidin-4-yl]méthylamino]éthoxy]bencil]thiazolidine-2,4-dione

lobeglitazona

(5*R*)-5-[4-(2-[[6-(4-metoxifenoxi)pirimidin-4-il]metilamino]etoxi)=bencil]-1,3-thiazolidina-2,4-diona

**lorcaserinum**



lorcaserin

(1*R*)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine

lorcasérine

(1*R*)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1*H*-3-benzazépine

lorcaserina

(1*R*)-8-cloro-1-metil-2,3,4,5-tetrahydro-1*H*-3-benzazepina**mifamurtidum**



mifamurtide

2-[[*N*-[(2*R*)-[(2-acetamido-2,3-dideoxy-D-glucopyranos-3-yl)oxy]=propanoyl]-L-alanyl-D-isoglutaminyl-L-alanyl]amino]ethyl (2*R*)-2,3-bis(hexadecanoyloxy)propyl hydrogen phosphate

mifamurtide

hydrogénophosphate de 2-[[*N*-[(2*R*)-2-[(3*R*,4*R*,5*S*,6*R*)-3-(acétylamino)-2,5-dihydroxy-6-(hydroxyméthyl)tétrahydro-2*H*-pyran-4-yloxy]propanoyl]-L-alanyl-D-isoglutaminyl-L-alanyl]amino]éthyle et de (2*R*)-2,3-bis(hexanoyloxy)propyle

mifamurtida

hidrógenofosfato de 2-[[*N*-[(2*R*)-2-[(3*R*,4*R*,5*S*,6*R*)-3-(acetilamino)-2,5-dihidroxi-6-(hidroximetil)tétrahidro-2*H*-piran-4-iloxi]propanoíl]-L-alaníl-D-isoglutaminíl-L-alaníl]amino]etilo y de (2*R*)-2,3-bis(hexanoiloxi)propilo**migalastatum**

migalastat



(2*R*,3*S*,4*R*,5*S*)-2-(hydroxymethyl)piperidine-3,4,5-triol

migalastat

(+)-(2*R*,3*S*,4*R*,5*S*)-2-(hydroxyméthyl)pipéridine-3,4,5-triol

migalastat

(2*R*,3*S*,4*R*,5*S*)-2-(hidroximetil)piperidina-3,4,5-triol



mirodenafilum
mirodenafil



5-ethyl-2-(5-[[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl]-2-propoxyphenyl)-7-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one

mirodénafil

5-éthyl-2-[5-[[4-(2-hydroxyéthyl)pipérazin-1-yl]sulfonyl]-2-propoxyphényl]-7-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one

mirodenafilo

5-etil-2-(5-[[4-(2-hidroxietyl)piperazin-1-il]sulfonyl]-2-propoxifenil)-7-propil-3,5-dihidro-4H-pirrol[3,2-d]pirimidin-4-ona



motavizumabum*
motavizumab

immunoglobulin G1, anti-(human respiratory syncytial virus glycoprotein F) humanized monoclonal MEDI-524; gamma1 heavy chain [humanized VH (*Homo sapiens* FR/*Mus musculus* CDR)-*Homo sapiens*IGHG1] (223-213')-disulfide with kappa light chain [humanized V-KAPPA (*Homo sapiens* FR/*Mus musculus* CDR)-*Homo sapiens*IGKC]; (229-229":232-232")-bisdisulfide dimer

motavizumab

immunoglobuline G1, anti-(glycoprotéine de fusion du virus syncytial respiratoire humain) anticorps monoclonal humanisé MEDI-524; chaîne lourde gamma1 [VH humanisé (*Homo sapiens* FR/*Mus musculus* CDR)-*Homo sapiens*IGHG1] (223-213')-disulfure avec la chaîne légère kappa [V-KAPPA humanisé (*Homo sapiens* FR/*Mus musculus* CDR)-*Homo sapiens*IGKC]; dimère (229-229":232-232")-bisdisulfure

motavizumab

inmunoglobulina G1, anti-(glicoproteína de fusión del virus sincitial respiratorio humano) anticuerpo monoclonal humanizado MEDI-524; cadena pesada gamma1 [VH humanizada (*Homo sapiens* FR/*Mus musculus* CDR)-*Homo sapiens*IGHG1] (223-213')-disulfuro con la cadena ligera kappa [V-KAPPA humanizada (*Homo sapiens* FR/*Mus musculus* CDR)-*Homo sapiens*IGKC]; (229-229":232-232")-bisdisulfide dimer

C₆₄₇₆H₁₀₀₁₄N₁₇₀₆O₂₀₀₈S₄₈

γ-1-Chain / Chaîne γ-1 / Cadena γ-1

QVTLRSGPA	LVKPTQTLTL	TCTFSGFSL	TAGMSVGWIR	QPPGKALEWL	50
ADIWDDKKH	YNPSLKDRLT	ISKDTSKNQV	VLKVTNMDPA	DTATYYCARD	100
MIFNFYFDVW	GQGTTVTVSS	ASTKGPSVFP	LAPSSKSTSG	GTAAALGCLVK	150
DYFPEPVTVS	WNSGALTSGV	HTFPAVLQSS	GLYSLSVVVT	VPSSSLGTQT	200
YICNVNHHKPS	NTKVDKRVEP	KSCDKHTHCP	PCPAPELLGG	PSVFLFPPKP	250
KDTLMISRTP	EVTGVVVDVS	HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	300
STYRVVSVLT	VLHQDWLNGK	EYCKKVSNA	LPAPIEKTIS	KAKGQPREPQ	350
VYTLPPSREE	MTKNQVSLTC	LVKGFYPSDI	AVEWESNGQP	ENNYKTTTPV	400
LDSDGSFFLY	SKLTVDKSRW	QQGNVFSCSV	MHEALHNHYT	QKSLSLSPGK	450

κ Chain / Chaîne κ / Cadena κ

DIQMTQSPST	LSASVGDRVT	ITCSASSRVG	YMHWYQQKPG	KAPKLLIYDT	50'
SKLASGVPSR	FSGSGSGTEF	TLTISSLQPD	DFATYYCFQG	SGYPFTFGGG	100'
TKVEIKRTVA	APSVFIFPPS	DEQLKSGTAS	VVCLLNNFYP	REAKVQWKVD	150'
NALQSGNSQE	SVTEQDSKDS	TYSLSSTLTL	SKADYEKHKV	YACEVTHQGL	200'
SSPVTKSFN	GEC				213'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

22-97 22"-97" 23-87" 23"-87" 133'-193' 133"-193" 147-203 147"-203"

213'-223 213"-223" 229-229" 232-232" 264-324 264"-324" 370-428 370"-428"

naproxcinodum


naproxcinod

4-(nitrooxy)butyl (2*S*)-2-(6-methoxynaphthalen-2-yl)propanoate

naproxcinod

(2*S*)-2-(6-méthoxynaphthalén-2-yl)propanoate de 4-(nitrooxy)butyle

naproxcinod

(2*S*)-2-(6-metoxinaftalen-2-il)propanoato de 4-(nitrooxi)butiloC₁₈H₂₁NO₆**omtriptolidum**


omtriptolide

4-[[[(3*bS*,4*aS*,5*aR*,6*R*,6*aS*,7*aS*,7*bS*,8*aS*,8*bS*)-8*b*-methyl-6*a*-(propan-2-yl)-1-oxo-1,3,3*b*,4,4*a*,6,6*a*,7*a*,7*b*,8*b*,9,10-dodecahydrotrisoxireno=[4*b*,5:6,7:8*a*,9]phenanthro[1,2-*c*]furan-6-yl]oxy]-4-oxobutanoic acid

omtriptolide

acide 4-[[[(3*bS*,4*aS*,5*aR*,6*R*,6*aS*,7*aS*,7*bS*,8*aS*,8*bS*)-8*b*-méthyl-6*a*-(1-méthyléthyl)-1-oxo-1,3,3*b*,4,4*a*,6,6*a*,7*a*,7*b*,8*b*,9,10-dodécahydrotrisoxiréno[4*b*,5:6,7:8*a*,9]phénanthro[1,2-*c*]furan-6-yl]=oxy]-4-oxobutanoïque

omtriptolida

ácido 4-[[[(3*bS*,4*aS*,5*aR*,6*R*,6*aS*,7*aS*,7*bS*,8*aS*,8*bS*)-8*b*-metil-6*a*-(propan-2-il)-1-oxo-1,3,3*b*,4,4*a*,6,6*a*,7*a*,7*b*,8*b*,9,10-dodecahidrotrisoxireno[4*b*,5:6,7:8*a*,9]fenantro[1,2-*c*]furan-6-il]oxi]-4-oxobutanoicoC₂₄H₂₈O₉

pafuramidinum


pafuramidine

4,4'-(furan-2,5-diyl)bis(*N*-methoxybenzenecarboximidamide)

pafuramidine

4,4'-(furane-2,5-diyl)bis(*N*-méthoxybenzèncarboximidamide)

pafuramidina

4,4'-(furano-2,5-diil)bis(*N*-metoxibencenocarboximidamida) $C_{20}H_{20}N_4O_3$ **pramiconazolum**


pramiconazole

1-(4-{4-[4-[(*2S,4R*)-4-(2,4-difluorophenyl)-4-[(1*H*-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-2-yl)methoxy]phenyl}piperazin-1-yl)phenyl)-3-(propan-2-yl)imidazolidin-2-one

pramiconazole

(+) -1-[4-[4-[4-[(*2S,4R*)-4-(2,4-difluorophényl)-4-[(1*H*-1,2,4-triazol-1-yl)méthyl]-1,3-dioxolan-2-yl]méthoxy]phényl]pipérazin-1-yl]phényl]-3-(1-méthyléthyl)imidazolidin-2-one

pramiconazol

1-(4-{4-[4-[(*2S,4R*)-4-(2,4-difluorofenil)-4-[(1*H*-1,2,4-triazol-1-il)metil]-1,3-dioxolan-2-il]metoxi]fenil}piperazin-1-il)fenil)-3-(propan-2-il)imidazolidin-2-ona $C_{35}H_{39}F_2N_7O_4$ **prinaberelum**

prinaberel


7-ethenyl-2-(3-fluoro-4-hydroxyphenyl)-1,3-benzoxazol-5-ol

prinabérel

7-éthényl-2-(3-fluoro-4-hydroxyphényl)-1,3-benzoxazol-5-ol

prinaberel

7-etenil-2-(3-fluoro-4-hidroxifenil)-1,3-benzoxazol-5-ol

 $C_{15}H_{10}FNO_3$ 

rilonaceptum*
rilonacept

[653-glycine][human interleukin-1 receptor accessory protein-(1-339)-peptide (extracellular domain fragment) fusion protein with human type 1 interleukin-1 receptor-(5-316)-peptide (extracellular domain fragment) fusion protein with human immunoglobulin G1-(229 C-terminal residues)-peptide (Fc fragment)], (659-659':662-662')-bisdisulfide dimer

rilonacept

(659-659':662-662')-bisdisulfure du dimère de la [653-glycine][protéine accessoire du récepteur de l'interleukine-1 humaine-(1-339)-peptide (fragment du domaine extracellulaire) protéine de fusion avec le récepteur de type I humain de l'interleukine-1-(5-316)-peptide (fragment du domaine extracellulaire) protéine de fusion avec l'immunoglobuline G1 humaine-(229 résidus C-terminaux)-peptide (fragment Fc)]

rilonacept

(659-659':662-662')-bisdisulfuro del dímero de la [653-glicina][proteína accesoria del receptor de la interleukina-1 humana-(1-339)-péptido (fragmento del dominio extracelular) proteína de fusión con el receptor de tipo I humano de la interleukina-1-(5-316)-péptido (fragmento del dominio extracelular) proteína de fusión con la inmunoglobulina G1 humana-(229 restos C-terminales)-péptido (fragmento Fc)]

C₉₀₃₀H₁₃₉₃₂N₂₄₀₀O₂₆₇₀S₇₄

Monomer / Monomère / Monómero					
SERCDDWGLD	TMRQIQVFED	EPARIKCPLF	EHFLKFNYST	AHSAGLTLIW	50
YWTRQDRDLE	EPINFRLPEN	RISKEKDVWL	FRPTLLNDTG	NYTCMLRNTT	100
YCSKVAFFLE	VVQKDSFCNS	PMKLPPVHKLY	IEYGIQRITC	PNVDGYFPSS	150
VKPTITWYMG	CYKIQNFNNV	IPEGMNLSEF	IALISNNGNY	TCVVTYPENG	200
RTFHLTRTLT	VKVVGSPKNA	VPPVIHSPND	HVVYEKEPGE	ELLIPCTVYF	250
SFLMDSRNEV	WWTIDGKKPD	DITIDVTINE	SISHSRTEDE	TRTQILSIKK	300
VTSEDLKRSY	VCHARSAKGE	VAKAAKVQKQ	VPAPRYTVEK	CKEREKIIIL	350
VSSANEIDVR	PCPLNPNEHK	GTITWYKDD	KTPVSTEQAS	RIHQHKEKLW	400
FVPAKVEDSG	HYCYVVRNSS	YCLRIKISAK	FVENEPNLGY	NAQAIFKQKL	450
PVAGDGGLVC	PYMEFFKNEN	NELPKLQWYK	DKPLLLDNI	HFSGVKDRLI	500
VMNVAEKHRG	NYTCHASYTY	LKGQYPITRV	IEFITLEENK	PTRPVIVSPA	550
NETMEVDLGS	QIQLICNVTG	QLSDIAYWKW	NGSVIDEDDP	VLGEDYYSVE	600
NPANKRRSTL	ITVLNISEIE	SRFYKHPFTC	FAKNTHGIDA	AYIQLIYPVT	650
NSGDKTHTCP	PCPAPELLGG	PSVFLFPPKP	KDTLMISRTP	EVTCTVVVDVS	700
HEDPEVKFNW	YVDGVEVHNA	KTKPREEQYN	STYRVVSVLT	VLHQDWLNGK	750
EYKCKVSNKA	LPAPIEKTIS	KAKGQPREPQ	VYTLPPSRDE	LTKNQVSLTC	800
LVKGFYPSDI	AVEWESNGQP	ENNYKTTPPV	LDSDGSFFLY	SKLTVDKSRW	850
QQGNVFSCSV	MHEALHNNHYT	QKSLSLSPGK			880

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
4-102' 4'-102' 27-94 27'-94' 117-161 117'-161' 140-192 140'-192' 246-312
246'-312' 341-422 341'-422' 362-414 362'-414' 339-482 339'-482' 460-514 460'-514'
566-630 566'-630' 659-659' 662-662' 694-754 694'-754' 800-858 800'-858'

rosabulinum
rosabulin



2-{3-[(4-cyanophenyl)methyl]indolizin-1-yl}-N-(3-methyl-1,2-thiazol-5-yl)-2-oxoacetamide

rosabuline

2-[3-(4-cyanobenzyl)indolizin-1-yl]-N-(3-méthylisothiazol-5-yl)-2-oxoacétamide

rosabulina

2-{3-[(4-cianofenil)metil]indolizin-1-il}-N-(3-metilisotiazol-5-il)-2-oxoacetamida

**sagopilonum**

sagipilone



(1*S*,3*S*,7*S*,10*R*,11*S*,12*S*,16*R*)-7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-1,3-benzothiazol-5-yl)-10-(prop-2-enyl)-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

sagopilone

(-)-(1*S*,3*S*,7*S*,10*R*,11*S*,12*S*,16*R*)-7,11-dihydroxy-8,8,12,16-tétraméthyl-3-(2-méthyl-1,3-benzothiazol-5-yl)-10-(prop-2-ényl)-4,17-dioxabicyclo[14.1.0]heptadécane-5,9-dione

sagopilona

(1*S*,3*S*,7*S*,10*R*,11*S*,12*S*,16*R*)-7,11-dihidroxi-8,8,12,16-tetrametil-3-(2-metil-1,3-benzotiazol-5-il)-10-(prop-2-enil)-4,17-dioxabicyclo[14.1.0]heptadecano-5,9-diona

**sodelglitazarum**

sodelglitazar



2-{4-[[{2-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl)methyl}sulfanyl]-2-methylphenoxy}-2-methylpropanoic acid

sodelglitazar

acide 2-[4-[[[2-[2-fluoro-4-(trifluorométhyl)phényl]-4-méthyl-1,3-thiazol-5-yl]méthyl]sulfanyl]-2-méthylphénoxy]-2-méthylpropanoïque

sodelglitazar

ácido 2-[4-[[{2-[2-fluoro-4-(trifluorometil)fenil]-4-metil-1,3-tiazol-5-il]metil]sulfanil]-2-metilfenoxi]-2-metilpropanoico



sofigatranum

sofigatran


propyl {(1*S*)-1-[(2*S*)-2-[(*trans*-4-aminocyclohexylmethyl)carbamoyl]=pyrrolidine-1-carbonyl]-2-methyl-2-[(propan-2-yl)sulfanyl]propyl}=carbamate

sofigatran

[(1*S*)-1-[(2*S*)-2-[(*trans*-4-aminocyclohexyl)méthyl]carbamoyl]=pyrrolidin-1-yl]carbonyl]-2-méthyl-2-[(1-méthyléthyl)sulfanyl]propyl]=carbamate de propyle

sofigatrán

[(1*S*)-1-[(2*S*)-2-[(*trans*-4-aminociclohexil)metil]carbamoil]pyrrolidin-1-il]carbonil]-2-metil-2-[(propan-2-il)sulfaniil]propil]carbamato de propilo

C₂₄H₄₄N₄O₄S**succinobucolum**

succinobucol


4-{4-[(2-{[3,5-di(*tert*-butyl)-4-hydroxyphenyl]sulfanyl}propan-2-yl)=sulfanyl]-2,6-di(*tert*-butyl)phenoxy}-4-oxobutanoic acid

succinobucol

acide 4-[4-[[1-[[3,5-bis(1,1-diméthyléthyl)-4-hydroxyphényl]sulfanyl]-1-méthyléthyl]sulfanyl]-2,6-bis(1,1-diméthyléthyl)phénoxy]-4-oxobutanoïque

succinobucol

ácido 4-[4-[(2-{[3,5-di(*terc*-butil)4-hidroxifenil]sulfaniil}propan-2-il)=sulfaniil]-2,6-di(*terc*-butil)fenoxi]-4-oxobutanoico

C₃₅H₅₂O₅S₂**taribavirinum**

taribavirin



1-β-D-ribofuranosyl-1*H*-1,2,4-triazole-3-carboximidamide

taribavirine

1-β-D-ribofuranosyl-1*H*-1,2,4-triazole-3-carboximidamide

taribavirina

1-β-D-ribofuranosil-1*H*-1,2,4-triazol-3-carboximidamida

**tezampanelum**



tezampanel

(3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-tetrazol-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid

tézampanel

(-)-acide (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-tétrazol-5-yl)éthyl]=
décahydroisoquinoléine-3-carboxylique

tezampanel

(-)-ácido (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-tetrazol-5-il)etil]=
decahidroisoquinolina-3-carboxílico**ticagrelorum**



ticagrelor

(1*S*,2*S*,3*R*,5*S*)-3-(7-[[[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]=
amino]-5-(propylsulfanyl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-
5-(2-hydroxyethoxy)cyclopentane-1,2-diol

ticagrélor

(1*S*,2*S*,3*R*,5*S*)-3-[7-[[[(1*R*,2*S*)-2-(3,4-difluorophényl)cyclopropyl]=
amino]-5-(propylsulfanyl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-
5-(2-hydroxyéthoxy)cyclopentane-1,2-diol

ticagrelor

(1*S*,2*S*,3*R*,5*S*)-3-(7-[[[(1*R*,2*S*)-2-(3,4-difluorofenil)ciclopropil]amino]-
5-(propilsulfanil)-3*H*-[1,2,3]triazolo[4,5-*d*]pirimidin-3-il)-
5-(2-hidroxietoxi)ciclopentano-1,2-diol

tigapotidum

tigapotide


L-glutamyl-L-tryptophyl-L-glutaminy-L-threonyl-L-aspartyl-L-asparaginy-L-S-[(acetamido)methyl]-L-cysteinyl-L-glutamyl-L-threonyl-S-[(acetamido)methyl]-L-cysteinyl-L-threonyl-S-[(acetamido)methyl]-L-cysteinyl-L-tyrosyl-L-glutamyl-L-threonine

tigapotide

S^{37} - S^{40} , S^{42} -tris[(acétylamino)méthyl]bêta-microsémipoprotéine humaine (protéine PSP94 sécrétée par la prostate)-(31-45)-peptide

tigapotida

S^{37} - S^{40} , S^{42} -tris[(acetylaminometil)]beta-microseminoproteína humana (proteína PSP94 secretada por la próstata)-(31-45)-péptido

 $C_{82}H_{119}N_{21}O_{34}S_3$
**tipelukastum**

tipelukast


4-(6-acetyl-3-{3-[(4-acetyl-3-hydroxy-2-propylphenyl)sulfanyl]=propoxy}-2-propylphenoxy)butanoic acid

tipelukast

acide 4-[6-acétyl-3-[3-[(4-acétyl-3-hydroxy-2-propylphényl)sulfanyl]=propoxy]-2-propylphénoxy]butanoïque

tipelukast

ácido 4-[6-acetil-3-[3-[(4-acetil-3-hidroxi-2-propilfenil)sulfanil]=propoxi]-2-propilfenoxi]butanoico

 $C_{29}H_{38}O_7S$
**tomopenemum**

tomopenem


(4*R*,5*S*,6*S*)-3-(((3*S*,5*S*)-5-[(3*S*)-3-(carbamimidamidoacetamido)=pyrrolidine-1-carbonyl]-1-methylpyrrolidin-3-yl)sulfanyl)-6-[(1*R*)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

tomopénem

(-)-acide (4*R*,5*S*,6*S*)-3-[[[(3*S*,5*S*)-5-[[[(3*S*)-3-[(carbamimidoylamino)=acétylamino]pyrrolidin-1-yl]carbonyl]-1-méthylpyrrolidin-3-yl]=sulfanyl]-6-[(1*R*)-1-hydroxyéthyl]-4-méthyl-7-oxo-1-azabicyclo[3.2.0]=hept-2-ène-2-carboxylique

tomopenem

ácido (4*R*,5*S*,6*S*)-3-[[[(3*S*,5*S*)-5-[[[(3*S*)-3-(carbamimidamidoacetamido)pirrolidin-1-il]carbonil]-1-metilpirrolidin-3-il]sulfanil]-6-[(1*R*)-1-hidroxietil]-4-metil-7-oxo-1-azabíciclo[3.2.0]=hept-2-eno-2-carboxílico

**tylvalosinum**

tylvalosin



(4*R*,5*S*,6*S*,7*R*,9*R*,11*E*,13*E*,15*R*,16*R*)-15-[[[(6-désoxy-2,3-di-*O*-méthyl-β-*D*-allopyranosyl)oxy]méthyl]-6-[[[3,6-didésoxy-4-*O*-[2,6-didésoxy-3-*C*-méthyl-4-*O*-(3-méthylbutanoyl)-α-*L*-ribo-hexopyranosyl]-3-(diméthylamino)-β-*D*-glucopyranosyl]oxy]-16-éthyl-5,9,13-triméthyl-2,10-dioxo-7-(2-oxoéthyl)oxacyclohexadeca-11,13-dien-4-yl]acétate

tylvalosine

(-)-acétate de (4*R*,5*S*,6*S*,7*R*,9*R*,11*E*,13*E*,15*R*,16*R*)-15-[[[(6-désoxy-2,3-di-*O*-méthyl-β-*D*-allopyranosyl)oxy]méthyl]-6-[[[3,6-didésoxy-4-*O*-[2,6-didésoxy-3-*C*-méthyl-4-*O*-(3-méthylbutanoyl)-α-*L*-ribo-hexopyranosyl]-3-(diméthylamino)-β-*D*-glucopyranosyl]oxy]-16-éthyl-5,9,13-triméthyl-2,10-dioxo-7-(2-oxoéthyl)oxacyclohexadéca-11,13-dièn-4-yle

tilvalosina

(-)-acetato de (4*R*,5*S*,6*S*,7*R*,9*R*,11*E*,13*E*,15*R*,16*R*)-15-[[[(6-desoxi-2,3-di-*O*-metil-β-*D*-alopiranosil)oxi]metil]-6-[[[3,6-didesoxi-4-*O*-[2,6-didesoxi-3-*C*-metil-4-*O*-(3-metilbutanoil)-α-*L*-ribo-hexopiranosil]-3-(dimetilamino)-β-*D*-glucopiranosil]oxi]-16-etil-5,9,13-trimetil-2,10-dioxo-7-(2-oxoetil)oxaciclohexadeca-11,13-dien-4-ilo

**vabicaserinum**

vabicaserin


(9*aR**,12*aS**)-4,5,6,7,9,9*a*,10,11,12,12*a*-decahydrocyclopenta[*c*][1,4]diazepino[6,7,1-*ij*]quinoline

vabicasérine

(-)-(9*aR**,12*aS**)-4,5,6,7,9,9*a*,10,11,12,12*a*-décahydrocyclopenta[*c*][1,4]diazépino[6,7,1-*ij*]quinoléine

vabicaserina

(-)-(9*aR**,12*aS**)-4,5,6,7,9,9*a*,10,11,12,12*a*-decahidrociclopenta[*c*][1,4]diazepino[6,7,1-*ij*]quinolina

$C_{15}H_{20}N_2$ 

or enantiomer, (-)-isomer
ou énantiomère, (-)-isomère
o enantiómero, (-)-isómero

vaptadinum


vaptadine

5,6-dihydrospiro(imidazo[2,1-*b*][3]benzazepine-11,4'-piperidine)-3-carboxamide

vaptadine

5,6-dihydrospiro[11*H*-imidazo[2,1-*b*][3]benzazépine-11,4'-pipéridine]-3-carboxamide

vaptadina

5,6-dihidrospiro(11*H*-imidazo[2,1-*b*][3]benzazepina-11,4'-piperidina)-3-carboxamida $C_{17}H_{20}N_4O$ **veliflaponum**


veliflapon

(2*R*)-cyclopentyl{4-[(quinolin-2-yl)methoxy]phenyl}acetic acid

véliflapon

(+) -acide (2*R*)-cyclopentyl[4-(quinoléin-2-ylméthoxy)phényl]acétique

veliflapon

(+) -ácido (2*R*)-ciclopentil[4-(quinolin-2-ilmetoxi)fenil]acético $C_{23}H_{23}NO_3$ **volinanserinum**

volinanserine



(R)-(2,3-dimethoxyphenyl){1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl}=methanol

volinansérine

(+) -(R)-(2,3-diméthoxyphényl)[1-[2-(4-fluorophényl)éthyl]pipéridin-4-yl]méthanol

volinanserina

(+) -(R)-(2,3-dimetoxifenil)[1-[2-(4-fluorofenil)etil]piperidin-4-il]metanol




**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Non Proprietary Names (Rec. INN): List 53
Dénominations communes internationales recommandées (DCI Rec.): Liste 53
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 53
(WHO Drug Information, Vol. 19, No. 1, 2005)

p. 80	<i>delete/supprimer/suprímase</i> gantacurium chloridum	<i>insert/insérer/insertése</i> gantacurii chloridum
-------	--	---

p. 88	panitumumabun panitumumab panitumumab panitumumab	<i>replace the molecular formula by the following</i> <i>remplacer la formule brute par la suivante</i> <i>sustitúyase la fórmula molecular por la siguiente</i>
-------	---	--



p. 88	pelitinibum pelitinib	<i>sustitúyase el nombre químico por el siguiente:</i> <i>(2E)-N-[3-ciano-4-[(3-cloro-4-fluorofenil)amino]-7-etoxiquinolin-6-il]-</i> <i>4-(dimetilamino)-2-butenamina</i>
-------	---------------------------------	--

Recommended International Non Proprietary Names (Rec. INN): List 55
Dénominations communes internationales recommandées (DCI Rec.): Liste 55
Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 55
(WHO Drug Information, Vol. 20, No. 1, 2006)

p. 45	<i>suprimáse</i> nebicapone	<i>insértese</i> nebicaona
-------	--------------------------------	-------------------------------

* Electronic structure available on Mednet: <http://mednet.who.int/>

* Structure électronique disponible sur Mednet: <http://mednet.who.int/>

* Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.